Recent developments The Turkish Medicines and Medical Devices Agency (the “TİTCK”) recently announced new procedures for the medicine licensing process depending on the payment status of the scientific analysis and assessment fees. Background Scientific analysis and assessment fees are among the mandatory fees in the medicine licensing process. In early January, the TİTCK announced an update to scientific analysis and assessment fees – including price tariffs – and stated that the deadline for the payment of scientific analysis and assessment fees was February 17, 2017. Companies that missed the payment deadline have had their license application waitlisted until November 30, 2017. Companies that do not pay their scientific analysis and assessment fees by November 30 will have their applications cancelled. For more information on scientific analysis and assessment fees, please refer to our previous legal alert of January 11, 2017. What the Announcement Says The TİTCK recently announced the following procedures on its website.
– If the laboratory analysis on the relevant products was initiated, the analysis will be completed; if the laboratory analysis has not yet been initiated, the analysis process will be suspended. – Upon the payment of the scientific analysis and assessment fees, the licensing process will resume as of the date notified by the TİTCK. – Priority or high priority applications will be fast-tracked for the active licensing process (the “Active Process List”) upon the payment of the scientific analysis and assessment fees. – The products listed on the Process Waiting List will be transferred to the Active Process List in accordance with the number of licensed products that were on the Active Process List and the licensing schedule. Applications transferred to the Active Process List will be announced within the first five working days of each month until November 30, 2017.
– Priority or high priority applications will be placed immediately on the Active Process List. – Other applications will be placed on the Active Process List only upon the payment of the scientific analysis and assessment fees.
– Priority or high priority applications will be placed on the Active Process List upon the payment of the scientific analysis and assessment fees. – The TİTCK will notify the applicant of the active process commencement date and the deadline for the payment of the scientific analysis and assessment fees. Such applications will be waitlisted until the commencement of the active process. The final waitlist and licensing process for 2018 will be announced in the December 2017 evaluation. Conclusion The TİTCK continues to provide pharmaceutical companies detailed guidelines on the medicine licensing process. Pharmaceutical companies should take note of the new procedural steps for their license applications and should follow future announcements made by the TİTCK. |
For further information,
please contact:
Legal Alerts
28/03/2017 09/06/2022
TİTCK Announces New Procedures for License Applications
Legal Alerts
Healthcare
General
Recommended for you
- Doing Business in Türkiye 2024
- Additional Customs Duty for Numerous Products
- Turkish Constitutional Court’s Decision on Freedom of Expression
- Important Developments in Customs Legislation
- Draft Circular on Bank Client Confidentiality Regulation Opened for consultation
- Turkey Publishes Preparation Guidelines on Turkish Pharmacopeia
- Court of Cassation Delivers Jurisprudential Unification Decision Subjecting All Domestic Arbitral Awards Rendered Following Effective Date of Code of Civil Procedure No. 6100 to Annulment Actions
- Innovations in the Turkish Capital Markets Law: Security Agent, Bondholders Meetings, Project Bonds
- Turkey Sovereign Fund – Details Revealed
- TİTCK Extends Validity Period of GMP Certificates
- Turkey Restructures Consumer Boards